LPTX
Leap Therapeutics Inc

10,390
Loading...
Loading...
News
all
press releases
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe
Stocktwits Contributor·8mo ago
News Placeholder
More News
News Placeholder
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline
While sirexatamab combined with tislelizumab and chemotherapy showed some activity in biomarker-specific populations, the study failed to generate a clear positive signal on progression-free survival endpoints.
Stocktwits·8mo ago
News Placeholder
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study...
PR Newswire·8mo ago
News Placeholder
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE...
PR Newswire·9mo ago
News Placeholder
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference PR Newswire CAMBRIDGE, Mass...
PR Newswire·10mo ago
News Placeholder
Leap Therapeutics Reports Third Quarter 2024 Financial Results
Leap Therapeutics Reports Third Quarter 2024 Financial Results Leap Therapeutics Reports Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Nov. 13, 2024 CAMBRIDGE, Mass., Nov. 13...
PR Newswire·11mo ago
News Placeholder
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Leap Therapeutics Announces Completion of Enrollment in...
PR Newswire·1y ago
News Placeholder
Leap Therapeutics Reports Second Quarter 2024 Financial Results
Leap Therapeutics Reports Second Quarter 2024 Financial Results Leap Therapeutics Reports Second Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Aug. 12, 2024 CAMBRIDGE, Mass., Aug. 12...
PR Newswire·1y ago
News Placeholder
Leap Therapeutics Reports First Quarter 2024 Financial Results
Leap Therapeutics Reports First Quarter 2024 Financial Results Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., May 13, 2024 CAMBRIDGE, Mass., May 13, 2024...
PR Newswire·1y ago
News Placeholder
Leap Therapeutics Announces $40 Million Private Placement
Leap Therapeutics Announces $40 Million Private Placement Leap Therapeutics Announces $40 Million Private Placement PR Newswire CAMBRIDGE, Mass., April 11, 2024 Net proceeds, along with existing...
PR Newswire·1y ago

Latest LPTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.